Make or break time for Iovance
Lifileucel heads up the list of upcoming US FDA catalysts.
CG gets money before data
CG Oncology and Arrivent pull off US flotations, and both offer speculative investment cases.
Carvykti joins Abecma in adcom limbo
Both BCMA-targeting Car-T therapies will face US advisory committee scrutiny after all.
Car-T comes full circle
Bristol renews its focus on chronic lymphocytic leukaemia, but rivals haven’t fared so well here.
